Syntheses of potential metabolites of a potent κ-opioid receptor agonist, TRK-820

Chemical and Pharmaceutical Bulletin

Volumn 52, Issue 6, 2004, Pages 670-674

  Kawamura, Kuniaki ^a   Horikiri, Hiromasa ^a   Hayakawa, Jun ^a   Seki, Chie ^a   Yoshizawa, Ken Ichi ^a   Umeuchi, Hideo ^a   Nagase, Hiroshi ^a  

^a TORAY INDUSTRIES INC   (Japan)

Author keywords

opioid receptor agonist; Glucuronide; Metabolite; TRK 820

Indexed keywords

17 CYCLOPROPYLMETHYL 4,5ALPHA EPOXY 14BETA HYDROXY 6BETA [N METHYL 3 (3 FURYL) 2 PROPENAMIDO]MORPHINAN 3 YL BETA DEXTRO GLUCOPYRANOSIDURONIC ACID; 4,5ALPHA EPOXY 14BETA HYDROXY 6BETA [N METHYL 3 (3 FURYL) 2 PROPENAMIDO]MORPHINAN 3 YL BETA DEXTRO GLUCOPYRANOSIDURONIC ACID; DRUG METABOLITE; KAPPA OPIATE RECEPTOR AGONIST; MORPHINE DERIVATIVE; N (4,5ALPHA EPOXY 3,14BETA DIHYDROXYMORPHINAN 6BETA YL) 3 (FURAN 3 YL) N METHYLPROP 2 ENAMIDE; NALFURAFINE; UNCLASSIFIED DRUG; KAPPA OPIATE RECEPTOR; MORPHINAN DERIVATIVE; SPIRO COMPOUND;

ALKYLATION; ARTICLE; GLUCURONIDATION; HUMAN; HUMAN CELL; LIVER CELL; METABOLITE; STEREOCHEMISTRY; SYNTHESIS; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY;

HEPATOCYTES; HUMANS; MORPHINANS; RECEPTORS, OPIOID, KAPPA; SPIRO COMPOUNDS;

EID: 16544375433     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.52.670     Document Type: Article

References (16)

1. Nagase H., Hayakawa J., Kawamura K., Kawai K., Takezawa Y., Matsuura H., Tajima C., Endo T., Chem. Pharm. Bull., 46, 366-369 (1998).
2. Togashi Y., Umeuchi H., Okano K., Ando N., Yoshizawa Y., Honda T., Kawamura K., Endoh T., Utsumi J., Kamei J., Tanaka T., Nagase H., Eur. J. Pharmacol., 435, 259-264 (2002).
3. Umeuchi H., Togashi Y., Honda T., Nakao K., Okano K., Tanaka T., Nagase H., Eur. J. Pharmacol., 477, 29-35 (2003).
4. Casy A. F., Parfitt R. T., "Opioid Analgesics Chemistry and Receptors," Plenum Press, New York, 1986, pp. 87-91.
5. Sayre L. M., Portoghese P. S., J. Org. Chem., 45, 3366-3368 (1980).
6. Halcomb R. L., Danishefsky S. J., J. Am. Chem. Soc., 111, 6661-6666 (1989).
7. Koenig W., Knorr E., Ber. Dtsch. Chem. Ges., 34, 957-981 (1901).
8. Schmidt R. R., Grundler G., Synthesis, 1981, 885-887 (1981).
9. Schmidt R. R., Angew. Chem. Int. Ed. Engl., 25, 212-235 (1986).
10. Fischer B., Nudelman A., Ruse M., Herzig J., Gottlieb H. E., J. Org. Chem., 49, 4988-4993 (1984).
11. Berrang B., Brine G. A., Carrol F. I., Synthesis, 1997, 1165-1168 (1997).
12. Hashimoto S., Umeo K., Sano A., Watanabe N., Nakajima M., Ikegami S., Tetrahedron Lett., 36, 2251-2254 (1995).
13. Lacy C., Sainsbury M., Tetrahedron Lett., 36, 3949-3950 (1995).
14. Brown R. T., Carter N. E., Lumbard K. W., Scheinmann F., Tetrahedron Lett., 36, 8661-8664 (1995).
15. The use of human hepatocytes was in compliance with the Declaration of Helsinki and approved by the Ethical Committee of Toray Research Laboratories.
16. Pharmacological studies were conducted in accordance with the guidelines for Care and Use of Laboratory Animals in Toray Research Laboratories.